Nominee Named for FDA Commissioner Image Banner

Nominee Named for FDA Commissioner

You are here

Nominee Named for FDA Commissioner

March 18, 2019

ANCOR is sharing this article by Politico because the Food and Drug Administration (FDA) has jurisdiction over the use of electronic shock devices, which ANCOR and its coalition partners are asking the FDA to ban. The FDA also has jurisdiction over certain medical products, which can sometimes be relevant to our members who purchase these products as part of the supports they offer to people with disabilities.

As shared by Politico:

“National Cancer Institute Director Norman “Ned” Sharpless will serve as acting FDA commissioner after current Commissioner Scott Gottlieb departs in about a month, HHS Secretary Alex Azar announced at a congressional hearing today.

The oncology doctor was appointed to head the institute, part of NIH, in June 2017 and quickly made modernizing research, diversifying clinical trials and improving outreach to underserved populations some of his signature issue areas.

[…]

Gottlieb has recommended that Sharpless be given the permanent post, according to people familiar with the current commissioner's thinking.”